Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGEN1777 |
Synonyms | |
Therapy Description |
AGEN1777 (BMS-986442) is a bispecific antibody targeting TIGIT and CD96, which potentially induces enhanced anti-tumor immune response (Cancer Res (2024) 84 (6_Supplement): 3915). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGEN1777 | AGEN-1777|AGEN 1777|BMS-986442|BMS986442|BMS 986442 | TIGIT Antibody 19 | AGEN1777 (BMS-986442) is a bispecific antibody targeting TIGIT and CD96, which potentially induces enhanced anti-tumor immune response (Cancer Res (2024) 84 (6_Supplement): 3915). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05025085 | Phase I | AGEN1777 AGEN1777 + unspecified PD-1 antibody | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Completed | USA | 0 |